TW202246286A - 作為hiv整合酶抑制劑之四環雜環化合物 - Google Patents
作為hiv整合酶抑制劑之四環雜環化合物 Download PDFInfo
- Publication number
- TW202246286A TW202246286A TW111105302A TW111105302A TW202246286A TW 202246286 A TW202246286 A TW 202246286A TW 111105302 A TW111105302 A TW 111105302A TW 111105302 A TW111105302 A TW 111105302A TW 202246286 A TW202246286 A TW 202246286A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- hiv
- ester
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149927P | 2021-02-16 | 2021-02-16 | |
| US63/149,927 | 2021-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202246286A true TW202246286A (zh) | 2022-12-01 |
Family
ID=80625127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111105302A TW202246286A (zh) | 2021-02-16 | 2022-02-14 | 作為hiv整合酶抑制劑之四環雜環化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11958864B2 (https=) |
| EP (1) | EP4294813B1 (https=) |
| JP (1) | JP2024507788A (https=) |
| KR (1) | KR20230147131A (https=) |
| CN (1) | CN117083282A (https=) |
| AR (1) | AR124868A1 (https=) |
| CA (1) | CA3208396A1 (https=) |
| ES (1) | ES3048138T3 (https=) |
| MX (1) | MX2023009445A (https=) |
| TW (1) | TW202246286A (https=) |
| WO (1) | WO2022177840A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| EP4704976A1 (en) * | 2023-04-28 | 2026-03-11 | Merck Sharp & Dohme LLC | Delivery devices for anti-hiv compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| JP5551697B2 (ja) * | 2008-07-25 | 2014-07-16 | ビーブ・ヘルスケア・カンパニー | 化合物 |
| ES2448766T3 (es) * | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Profármacos de dolutegravir |
| DK2620436T3 (en) * | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| EP3573984A4 (en) * | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS |
-
2022
- 2022-02-14 MX MX2023009445A patent/MX2023009445A/es unknown
- 2022-02-14 ES ES22707560T patent/ES3048138T3/es active Active
- 2022-02-14 US US17/670,689 patent/US11958864B2/en active Active
- 2022-02-14 EP EP22707560.3A patent/EP4294813B1/en active Active
- 2022-02-14 CN CN202280022034.3A patent/CN117083282A/zh active Pending
- 2022-02-14 TW TW111105302A patent/TW202246286A/zh unknown
- 2022-02-14 WO PCT/US2022/016261 patent/WO2022177840A1/en not_active Ceased
- 2022-02-14 CA CA3208396A patent/CA3208396A1/en active Pending
- 2022-02-14 JP JP2023548941A patent/JP2024507788A/ja active Pending
- 2022-02-14 KR KR1020237031339A patent/KR20230147131A/ko active Pending
- 2022-02-14 AR ARP220100289A patent/AR124868A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022223241A1 (en) | 2023-08-24 |
| EP4294813A1 (en) | 2023-12-27 |
| AR124868A1 (es) | 2023-05-10 |
| US20220259227A1 (en) | 2022-08-18 |
| KR20230147131A (ko) | 2023-10-20 |
| MX2023009445A (es) | 2023-08-25 |
| US11958864B2 (en) | 2024-04-16 |
| WO2022177840A1 (en) | 2022-08-25 |
| JP2024507788A (ja) | 2024-02-21 |
| ES3048138T3 (en) | 2025-12-09 |
| EP4294813B1 (en) | 2025-09-10 |
| CA3208396A1 (en) | 2022-08-25 |
| CN117083282A (zh) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9951079B2 (en) | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors | |
| TW202246286A (zh) | 作為hiv整合酶抑制劑之四環雜環化合物 | |
| EP3397639B1 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
| US10233193B2 (en) | Fused tricyclic heterocyclic compounds useful for treating HIV infection | |
| EP3752144B1 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
| US10548910B2 (en) | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors | |
| US10624912B2 (en) | Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors | |
| US10544155B2 (en) | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | |
| EP3801543B1 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
| US10934312B2 (en) | Tricyclic heterocycle compounds useful as HIV integrase inhibitors | |
| WO2014014933A1 (en) | Hiv treatment with amido-substituted pyrimidinone derivatives | |
| US20150203512A1 (en) | Macrocyclic compounds as hiv integrase inhibitors | |
| US10786488B2 (en) | Substituted quinolizine derivatives useful as HIV integrase inhibitors | |
| KR20210005139A (ko) | Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물 | |
| RU2851203C2 (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| AU2022223241B2 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| US20210115044A1 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |